Download PDF

1. Company Snapshot

1.a. Company Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines.The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.


The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd.BioCryst Pharmaceuticals, Inc.was founded in 1986 and is headquartered in Durham, North Carolina.

Show Full description

1.b. Last Insights on BCRX

BioCryst Pharmaceuticals' recent performance was driven by strong Q4 2025 earnings, with quarterly earnings of $1.12 per share beating estimates. The company's consensus recommendation is "Moderate Buy" from thirteen analysts, with ten issuing a buy rating. BioCryst also granted restricted stock units to newly-hired employees, totaling 65,850 shares. Additionally, the company reported inducement grants under Nasdaq Listing Rule 5635(c)(4), further solidifying its growth prospects. Institutional investors, including Alkeon Capital Management LLC, continue to show confidence in the company.

1.c. Company Highlights

2. BioCryst's Strong FY 2025 Performance and Future Growth Prospects

BioCryst reported a robust financial performance for FY 2025, with non-GAAP total revenue increasing by 45% year-on-year, driven by a 43% growth in ORLADEYO revenues. The company's non-GAAP operating profit surged to $214 million, representing a 198% year-on-year increase, the highest ever in BioCryst's history. Earnings per share (EPS) came in at $1.12, significantly beating analyst estimates of $0.07. The strong revenue growth was partly driven by a 9% price increase in January, which is expected to net around 4.5%.

Publication Date: Mar -05

📋 Highlights
  • ORLADEYO Revenue Growth: Full-year 2025 revenue reached $601.8M (+38% YoY; +43% excluding Europe divestiture).
  • Non-GAAP Operating Profit: Q4 2025 reported $214M operating profit (198% YoY increase), highest in BioCryst's history.
  • Pediatric HAE Market Expansion: FDA approved ORLADEYO pellets for children aged 2–12 in December 2025, addressing underdiagnosed pediatric HAE populations.
  • Navenibart Phase III Trial: Enrollment of 145 patients expected to complete by mid-2026, focusing on 3-month dosing regimens for HAE prophylaxis.

Segment Performance and Growth Drivers

The company's HAE portfolio, including ORLADEYO, continues to drive growth. ORLADEYO revenue reached $601.8 million, up 38% for the year and 43% excluding the Europe business sold in October. The recent approval of ORLADEYO oral pellets for children aged 2 to less than 12 is expected to be a significant growth driver, addressing a significant unmet need in younger kids with HAE. As Charlie Gayer mentioned, "Availability of a safe, effective, and targeted oral prophy has the potential to change how kids with HAE grow up."

Pipeline Advancements and Future Expectations

BioCryst is making progress in its pipeline, with the Navenibart pivotal Phase III trial continuing to recruit well, expected to complete enrollment around mid-2026. The company expects full-year 2026 non-GAAP OpEx to be between $450 million and $470 million. Analysts estimate revenue growth at 13.6% for the next year, indicating a continued strong performance.

Valuation and Metrics

Using the provided valuation metrics, BioCryst's P/E Ratio stands at 6.85, and the P/S Ratio is 2.06. The EV/EBITDA ratio is 6.22, indicating a relatively reasonable valuation. The company's ROIC is high at 93.94%, suggesting efficient use of capital. However, the ROE is negative at -76.45%, which may be a concern. The Net Debt / EBITDA ratio is 1.1, indicating a manageable debt position. The Free Cash Flow Yield is 18.26%, which is attractive.

3. NewsRoom

Card image cap

Alkeon Capital Management LLC Trims Position in BioCryst Pharmaceuticals, Inc. $BCRX

Mar -15

Source: defenseworld.net

Card image cap

Avoro Capital Advisors LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX

Mar -14

Source: defenseworld.net

Card image cap

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar -04

Source: globenewswire.com

Card image cap

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Feb -27

Source: defenseworld.net

Card image cap

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript

Feb -26

Source: seekingalpha.com

Card image cap

BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates

Feb -26

Source: zacks.com

Card image cap

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

Feb -26

Source: globenewswire.com

Card image cap

GSA Capital Partners LLP Acquires 78,827 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Feb -18

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.27%)

6. Segments

Oral Small Molecule and Protein Therapeutics

Expected Growth: 9.27%

BioCryst Pharmaceuticals' Oral Small Molecule and Protein Therapeutics segment growth is driven by increasing demand for convenient, orally administered treatments, advancements in protein therapeutics, and the company's strong pipeline of novel compounds. Additionally, growing prevalence of diseases such as hereditary angioedema and increasing adoption of oral therapies over injectables contribute to the 9.27% growth.

7. Detailed Products

Rapivab

Rapivab is an antiviral medication used to treat and prevent influenza (flu) in adults and children.

BCX9930

BCX9930 is an oral, small molecule factor D inhibitor being developed for the treatment of complement-mediated diseases.

BCX9250

BCX9250 is an oral, small molecule inhibitor of plasma kallikrein being developed for the treatment of hereditary angioedema (HAE).

BCX7353

BCX7353 is an oral, small molecule inhibitor of plasma kallikrein being developed for the prevention of hereditary angioedema (HAE) attacks.

8. BioCryst Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

BioCryst Pharmaceuticals, Inc. operates in a highly competitive industry, but the threat of substitutes is mitigated by the company's focus on developing novel oral serine protease inhibitors for the treatment of hereditary angioedema.

Bargaining Power Of Customers

BioCryst Pharmaceuticals, Inc. has a diverse customer base, including pharmaceutical companies and research institutions, which reduces the bargaining power of individual customers.

Bargaining Power Of Suppliers

BioCryst Pharmaceuticals, Inc. relies on a limited number of suppliers for raw materials and services, which gives them some bargaining power, but the company's strong relationships with suppliers mitigate this risk.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services, posing a significant threat to BioCryst Pharmaceuticals, Inc.'s market share.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players and new entrants vying for market share, leading to a high intensity of rivalry that BioCryst Pharmaceuticals, Inc. must navigate.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 219.26%
Debt Cost 12.74%
Equity Weight -119.26%
Equity Cost 13.75%
WACC 11.53%
Leverage -183.85%

11. Quality Control: BioCryst Pharmaceuticals, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
BioCryst Pharmaceuticals

A-Score: 4.9/10

Value: 7.0

Growth: 7.2

Quality: 6.0

Yield: 0.0

Momentum: 5.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Arbutus Biopharma

A-Score: 4.6/10

Value: 6.0

Growth: 4.0

Quality: 4.1

Yield: 0.0

Momentum: 9.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Ocular Therapeutix

A-Score: 4.3/10

Value: 6.2

Growth: 5.0

Quality: 4.4

Yield: 0.0

Momentum: 8.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Poseida Therapeutics

A-Score: 4.1/10

Value: 4.5

Growth: 4.8

Quality: 4.7

Yield: 0.0

Momentum: 7.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
EyePoint Pharmaceuticals

A-Score: 4.0/10

Value: 6.2

Growth: 2.2

Quality: 4.9

Yield: 0.0

Momentum: 9.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Lipocine

A-Score: 3.8/10

Value: 7.7

Growth: 6.8

Quality: 2.7

Yield: 0.0

Momentum: 3.0

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

9.7$

Current Price

9.7$

Potential

-0.00%

Expected Cash-Flows